期刊文献+

温阳通络方基于miR-26b-3p调控类风湿关节炎滑膜成纤维细胞的机制研究

Mechanism of Wenyang Tongluo Prescription in Regulating Synovial Fibroblasts in Rheumatoid Arthritis Based on MiR-26b-3p
下载PDF
导出
摘要 目的:探讨温阳通络方基于微小RNA(miR)-26b-3p调控类风湿关节炎滑膜成纤维细胞增殖、迁移、侵袭的作用。方法:SD大鼠随机分为温阳通络方组和空白血清组。温阳通络方组大鼠给药剂量为4.05 g·kg^(-1)·d^(–1),2次/d,间隔12 h,连续给药3 d,末次给药后1 h腹主动脉取血分离血清;细胞计数试剂盒-8(CCK-8)实验筛选温阳通络方含药血清最佳浓度和干预时间;在人类风湿关节炎滑膜成纤维细胞MH7A中分别转染inhibitor NC、miR-26b-3p inhibitor、mimic NC、miR-26b-3p mimic片段,并用温阳通络方含药血清干预,设置正常关节成纤维样滑膜细胞为对照组,实时定量聚合酶链式反应(qRT-PCR)检测MH7A细胞中miR-26b-3p的表达;CCK-8实验检测各组细胞的增殖情况;Transwell实验检测各组细胞的迁移、侵袭情况。结果:不同浓度温阳通络方含药血清均能上调miR-26b-3p的表达(P<0.05),miR-26b-3p的表达呈浓度依赖性升高。温阳通络方含药血清干预MH7A细胞后,细胞的增殖、迁移、侵袭能力减弱(P<0.05)。miR-26b-3p过表达后,MH7A细胞的增殖、迁移、侵袭能力减弱(P<0.05);干扰miR-26b-3p的表达后,MH7A细胞的增殖、迁移、侵袭能力增强(P<0.05)。在干扰miR-26b-3p表达的基础上,温阳通络方含药血清干预MH7A细胞后,细胞的增殖、迁移、侵袭能力减弱(P<0.05)。结论:温阳通络方通过上调miR-26b-3p的表达抑制类风湿关节炎滑膜成纤维细胞的增殖、迁移、侵袭。 Objective:To investigate the regulatory effect of Wenyang Tongluo Prescription on the proliferation,migration,and invasion of synovial fibroblasts in rheumatoid arthritis based on miR-26b-3p.Methods:SD rats were randomly divided into a Wenyang Tongluo Prescription group and a blank serum group.The Wenyang Tongluo Prescription group was given Wenyang Tongluo Prescription at 4.05 g·kg^(-1)·d^(–1),twice daily,with a 12-hour interval,for 3 consecutive days.Blood was collected from the abdominal aorta 1 hour after the last administration,followed by serum isolation.The Cell Counting Kit-8(CCK-8)assay was used to determine the optimal concentration and intervention time of Wenyang Tongluo Prescription-containing serum.Human rheumatoid arthritis synovial fibroblasts(MH7A)were transfected with inhibitor NC,miR-26b-3p inhibitor,mimic NC,and miR-26b-3p mimic,respectively,and treated with Wenyang Tongluo Prescription-containing serum.Human fibroblast-like synovial cells(HFLS)were set as the blank control group.Real-time quantitative PCR(qRT-PCR)was used to detect the expression of miR-26b-3p in MH7A cells.The proliferation of cells in each group was detected by the CCK-8 assay.The migration and invasion of cells in each group were detected by the Transwell assay.Results:The expression of miR-26b-3p was upregulated by serum containing Wenyang Tongluo Prescription at different concentrations(P<0.05),and the expression of miR-26b-3p increased in a concentration-dependent manner.After the intervention with the drug-containing serum of Wenyang Tongluo Prescription,the proliferation,migration,and invasion abilities of MH7A cells were weakened(P<0.05).After miR-26b-3p overexpression,the proliferation,migration,and invasion of MH7A cells were weakened(P<0.05).After interfering with the expression of miR-26b-3p,the proliferation,migration,and invasion of MH7A cells were enhanced(P<0.05).On the basis of interfering with the expression of miR-26b-3p,the proliferation,migration,and invasion of MH7A cells were weakened after intervention with the drug-containing serum of Wenyang Tongluo Prescription(P<0.05).Conclusion:Wenyang Tongluo Prescription can inhibit the proliferation,migration,and invasion of synovial fibroblasts in rheumatoid arthritis by upregulating the expression of miR-26b-3p.
作者 李冬艳 田亚丹 宋佳欣 罗定霞 吴晶金 LI Dong-yan;TIAN Ya-dan;SONG Jia-xin;LUO Ding-xia;WU Jing-jin(The First Clinical Medical College of Yunnan University of Traditional Chinese Medicine,Kunming 650011,China;Department of Rheumatology,Yunnan Provincial Hospital of Traditional Chinese Medicine,Kunming 650021,China)
出处 《中国现代中药》 CAS 2024年第10期1719-1726,共8页 Modern Chinese Medicine
基金 国家自然科学基金项目(82360924) 云南省中医联合专项重点项目(202101AZ070001-161) 兴滇英才“青年人才”项目 云南省高层次中医痹病学后备人才项目。
关键词 类风湿关节炎 微小RNA-26b-3p 温阳通络方 滑膜成纤维细胞 rheumatoid arthritis miR-26b-3p Wenyang Tongluo Prescription synovial fibroblasts
  • 相关文献

参考文献13

二级参考文献173

  • 1胡大伟,鲍春德,陈顺乐,古洁若,栗占国,孙凌云,韩星海,倪立青.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎双盲随机多中心对照临床研究[J].中华风湿病学杂志,2005,9(11):664-668. 被引量:86
  • 2周茹,杨以阜,左建平.Ⅱ型胶原诱导的小鼠关节炎动物模型的建立及影响因素[J].中国药理学通报,2006,22(12):1532-1535. 被引量:28
  • 3赵昆,高明.非神经源性恶性肿瘤嗜神经侵袭机制研究进展[J].中华肿瘤防治杂志,2007,14(10):795-798. 被引量:1
  • 4国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1997.197.
  • 5国家药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002.68.
  • 6郑筱萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社.2004:58.
  • 7Cathcart ES,O'Sullivan JB.Rheumatoid arthritis in a New England town.A prevalence study in Sudbury,Massachusetts.N Engl J Med,1970; 282(8):421-424.
  • 8Linos A,Worthington JW,O'Fallon WM,et al.The epidemiology of rheumatoid arthritis in Rochester,Minnesota:a study of incidence,prevalence,and mortality.Am J Epidemiol,1980; 111(1):87-98.
  • 9Costenbader KH,Chang SC,Laden F,et al.Geographic variation in rheumatoid arthritis incidence among women in the United States.Arch Intern Med,2008; 168(15):1664-1670.
  • 10Lindqvist UR,Alenius GM,Husmark T,et al.The Swedish early psoriatic arthritis register.2-year followup:a comparison with early rheumatoid arthritis.J Rheumatol,2008; 35(4):668-673.

共引文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部